Edition:
United Kingdom

Adocia SA (ADOC.PA)

ADOC.PA on Paris Stock Exchange

13.90EUR
3:17pm BST
Change (% chg)

€-6.60 (-32.20%)
Prev Close
€20.50
Open
€13.96
Day's High
€14.98
Day's Low
€13.50
Volume
374,458
Avg. Vol
26,484
52-wk High
€22.60
52-wk Low
€10.06

Latest Key Developments (Source: Significant Developments)

Adocia H1 Net Income Loss of EUR 13.0 Million
Wednesday, 17 Jul 2019 

July 17 (Reuters) - ADOCIA SA ::CASH POSITION OF NEARLY 21 MILLION EUROS END OF JUNE 2019.OPERATING EXPENSES FOR FIRST SIX MONTHS OF 2019 AMOUNT TO 18.1 MILLION EUROS.H1 NET INCOME LOSS OF EUR 13.0 MILLION VERSUS PROFIT OF EUR 10.6 MILLION YEAR AGO.H1 REVENUE EUR 1.7 MILLION VERSUS EUR 32.8 MILLION YEAR AGO.  Full Article

Adocia Initiates 3-Week Phase 1B Study Of ADO09
Thursday, 6 Jun 2019 

June 6 (Reuters) - ADOCIA SA ::ADOCIA INITIATES A 3-WEEK PHASE 1B STUDY OF ADO09, A CO-FORMULATION OF PRAMLINTIDE AND MEALTIME INSULIN, IN PEOPLE WITH TYPE 1 DIABETES.STUDY COMPLETION IS EXPECTED IN Q4 2019.PRIMARY ENDPOINT IS EFFECT OF ADO09, COMPARED TO PRANDIAL INSULIN NOVOLOG(®), ON POSTPRANDIAL GLYCEMIC CONTROL AT END OF A 24-DAY TREATMENT PERIOD.THIS STUDY WILL DOCUMENT THE SAFETY AND EFFICACY OF ADO09 OVER A 24-DAY PERIOD OF REPEAT ADMINISTRATION, INCLUDING AN OUTPATIENT PORTION, AIMING TO INFORM FURTHER CLINICAL DEVELOPMENT.  Full Article

Adocia Announces Positive Topline Results For First Clinical Study Of ADO09
Tuesday, 9 Apr 2019 

April 9 (Reuters) - ADOCIA SA ::ADOCIA ANNOUNCES POSITIVE TOPLINE RESULTS FOR THE FIRST CLINICAL STUDY OF ADO09, A NEW CO-FORMULATION OF PRAMLINTIDE AND A PRANDIAL INSULIN ANALOG, IN PEOPLE WITH TYPE 1 DIABETES.ADO09 IS FIRST CO-FORMULATION OF PRAMLINTIDE AND RAPID-ACTING A21G HUMAN INSULIN ANALOG, METABOLITE OF INSULIN GLARGINE.ADO09 SHOWED A SIGNIFICANT 85% DECREASE IN BLOOD GLUCOSE EXCURSION OVER FIRST TWO HOURS AFTER A MEAL COMPARED TO HUMALOG.ADO09 SHOWED SIMILAR GLUCOSE CONTROL OVER FIRST TWO HOURS AFTER A MEAL COMPARED TO SEPARATE INJECTIONS OF SYMLIN AND HUMULIN.ALL TREATMENTS WERE WELL TOLERATED.WE WILL NOW MOVE QUICKLY INTO A PHASE 2 CLINICAL TRIAL.".EXPECTS TO LAUNCH A PHASE 1/2, OUTPATIENT, 3-WEEK TRIAL OF ADO09 DURING THIS QUARTER.  Full Article

Adocia FY Revenue Up At 47.4 Million Euros
Tuesday, 12 Mar 2019 

March 12 (Reuters) - ADOCIA SA ::ADOCIA ANNOUNCES ITS FINANCIAL RESULTS FOR 2018: HIGHER REVENUE AND REINFORCED CASH POSITION.CASH POSITION OF APPROXIMATELY EUR 40 MILLION ON DECEMBER 31(ST), 2018 COMPARED TO EUR 35 MILLION ON DECEMBER 31(ST), 2017.2018 A TURNOVER OF EUR 47.4 MILLION.FY GROUP NET INCOME EUR 7.6 MILLION VERSUS LOSS OF EUR 8.6 MILLION YEAR AGO.FY OPERATING INCOME EUR 9.7 MILLION VERSUS LOSS OF EUR 8.2 MILLION YEAR AGO.  Full Article

Adocia Announces Clinical Trial Evaluating BioChaperone Lispro
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - ADOCIA SA ::ADOCIA ANNOUNCES A CLINICAL TRIAL EVALUATING BIOCHAPERONE® LISPRO AND OTHER RAPID-ACTING INSULIN ANALOGS USING ILETTM BIONIC PANCREAS.FIRST TRIAL TO TEST ULTRA-RAPID INSULIN BIOCHAPERONE LISPRO WITH AUTOMATED INSULIN DELIVERY.USING INSULIN-ONLY CONFIGURATION OF ILET BIONIC PANCREAS SYSTEM, THIS TRIAL WILL INVESTIGATE EFFECT OF DIFFERENT PHARMACOKINETIC CHARACTERISTICS OF INSULIN ASPART, INSULIN LISPRO, AND ULTRA-RAPID BIOCHAPERONE LISPRO ON GLYCEMIC CONTROL.  Full Article

Adocia And Tonghua Dongbao Announce Global Supply Agreements
Friday, 1 Jun 2018 

June 1 (Reuters) - ADOCIA SA ::ADOCIA AND TONGHUA DONGBAO ANNOUNCE GLOBAL SUPPLY AGREEMENTS FOR INSULIN LISPRO AND INSULIN GLARGINE.TONGHUA DONGBAO (THDB) WILL MANUFACTURE AND SUPPLY INSULIN GLARGINE AND INSULIN LISPRO TO ADOCIA WORLDWIDE, EXCLUDING CHINA.AGREEMENTS EXPAND PREVIOUSLY ANNOUNCED STRATEGIC ALLIANCE BETWEEN BOTH COMPANIES.  Full Article

Adocia FY Operating Revenue Down At 27.2‍​ Million Euros
Monday, 19 Mar 2018 

March 19 (Reuters) - ADOCIA SA ::‍CASH POSITION OF APPROXIMATELY EUR 35 MILLION ON DECEMBER 31(ST), 2017​.FY OPERATING REVENUE EUR 27.2‍​ MILLION VERSUS EUR 30.5 MILLION YEAR AGO.FY NET LOSS EUR ‍8.5​ MILLION VERSUS LOSS OF EUR 7.9 MILLION YEAR AGO.FY REVENUE EUR 19.5 MILLION VERSUS EUR 22.5 MILLION YEAR AGO‍​.FY LOSS FROM ORDINARY OPERATING EXPENSES EUR ‍​8.2 MILLION VERSUS LOSS OF EUR 8.0 MILLION YEAR AGO.FY OPERATING LOSS EUR 8.2 MILLION VERSUS LOSS OF EUR 8.0 MILLION YEAR AGO‍​.  Full Article

Adocia Files Additional Arbitration Claims Against Eli Lilly & Company​
Tuesday, 6 Feb 2018 

Feb 6 (Reuters) - ADOCIA SA ::‍ADOCIA FILES ADDITIONAL ARBITRATION CLAIMS AGAINST ELI LILLY & COMPANY <<>>​.‍SEEKS DAMAGES OF USD 200 MILLION AND OTHER RELIEF ON CONFIDENTIAL INFORMATION ABUSE AND AGREEMENT BREACHES.EXPECT A DECISION ON THIS CLAIM IN Q2 OF 2018.‍WILL PROVIDE NO ADDITIONAL COMMENT ON THE PROCEEDINGS UNTIL THEIR CONCLUSION​.  Full Article

Adocia Announces Expanded Biochaperone Product Portfolio Beyond Diabetes
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - ADOCIA SA ::ADOCIA ANNOUNCES EXPANDED BIOCHAPERONE® PRODUCT PORTFOLIO BEYOND DIABETES.BIOCHAPERONE TO BE DEPLOYED IN SELECTED RANGE OF INJECTABLE THERAPEUTICS ACROSS NUMEROUS THERAPEUTIC AREAS​.‍INITIAL PROGRAMS ADDED INCLUDE READY-TO-INJECT VERSION OF TEDUGLUTIDE FOR TREATMENT OF SHORT BOWEL SYNDROME​.‍INITIAL PROGRAMS ADDED INCLUDE FIXED DOSE COMBINATION OF GLUCAGON AND EXENATIDE FOR TREATMENT OF OBESITY​.‍EXPANSION OF PORTFOLIO CREATES NEW PARTNERSHIP OPPORTUNITIES​.  Full Article

Adocia reports topline results of Biochaperone Glucagon Phase 1 study
Monday, 20 Nov 2017 

Nov 20 (Reuters) - ADOCIA SA ::ADOCIA REPORTS TOPLINE RESULTS OF BIOCHAPERONE® GLUCAGON PHASE 1 STUDY.‍BIOCHAPERONE GLUCAGON WAS FOUND TO BE SAFE AND WELL TOLERATED IN PEOPLE WITH TYPE 1 DIABETES​.‍BIOCHAPERONE GLUCAGON DEMONSTRATED EFFICACY IN RESCUING PARTICIPANTS FROM MEDICALLY INDUCED HYPOGLYCEMIA IN MEDIAN TIME OF 11 MINS​.  Full Article

French and Benelux stocks-Factors to watch

PARIS, Aug 23 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.